You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 5,504,001

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,504,001

Title:	Hybrid plasminogen activator
Abstract:	Hybrid proteins comprising a cross-linking domain derived from a protein that acts as an acyl-donor substrate for factor XIIIa, a fibrin-binding domain, and a serine protease domain are disclosed. Host cells transfected or transformed with an expression vector comprising a transcriptional promoter operably linked to a DNA sequence encoding such hybrid proteins are also disclosed, as well as methods for producing the proteins. The proteins may be utilized in combination with a suitable carrier or diluent as pharmaceutical compositions.
Inventor(s):	Foster; Donald C. (Seattle, WA)
Assignee:	ZymoGenetics, Inc. (Seattle, WA)
Application Number:	08/254,485
Patent Claims:	1. A hybrid plasminogen activator comprising a human tissue plasminogen activator or a variant thereof having one or more amino acid substitutions within the cleavage site sequence Gln-Phe-Arg-Ile-Lys-Gly-Gly, and an amino-terminal cross-linking domain, wherein the cross-linking domain comprises the amino terminal twelve amino acids of .alpha..sub.2 -plasmin inhibitor. 2. A hybrid plasminogen activator having the sequence Ser-Asn-Gln-Glu-Glm-Val-Ser-Pro-Leu-Thr-Gly-Leu-Lys-Gly-Ser-tPA, wherein tPA is human tissue plasminogen activator or a variant thereof having one or more amino acid substitutions within the cleavage site sequence Gln-Phe-Arg-Ile-Lys-Gly-Gly. 3. The plasminogen activator of claim 1 wherein the Arg residue in the cleavage site sequence is replaced with a Gly residue. 4. The plasminogen activator of claim 1 wherein said activator contains a thrombin cleavage site between the fibrin-binding domain and the serine protease domain. 5. The plasminogen activator of claim 4 wherein the Phe residue in the cleavage site sequence is replaced with a Pro residue. 6. A pharmaceutical composition comprising a plasminogen activator according to claim 1 in combination with a physiologically acceptable carrier or diluent. 7. The composition of claim 6 wherein said carrier or diluent is sterile water or sterile saline.

Details for Patent 5,504,001

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2013-04-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.